Sunday, June 4, 2017

Adventures in Capitalism: Outcry Over EpiPen Prices Hasn’t Made Them Lower

Mylan has an effective monopoly on a lifesaving product, which has allowed its leaders to see public outrage as a tax they must pay.

via NYT > Your Money http://ift.tt/2qQu87u




via WordPress http://ift.tt/2sG9Aec
Posted by at
Labels: , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)